Figure 3.Clinical evaluation and identification of signaling pathways associated with CXCR4/DLC1/MAP1LC3C. (A, B) Expression of CXCR4/DLC1/MAP1LC3C in different grade stage, clinical stage, T stage and age groups in patients with GC. (C–F) CXCR4, DLC1, and MAP1LC3C are significantly enriched in pathways related to immune response and cancer in GSEA (FDR < 0.25, NP < 0.05).
